Spring Bank Pharmaceuticals, a developer of therapeutics for the treatment of viral infections, has appointed Martin Driscoll as President and Chief Executive.
Driscoll has more than three decades of experience leading biopharmaceutical companies through the clinical development and commercialisation of innovative therapies. He replaces Douglas Jensen, who is leaving the company to pursue other opportunities. Driscoll has also been elected to the company's Board of Directors.
The Milford, MA, US-based company also announces that Kurt Eichler has been elected to the Board of Directors.Most recently Driscoll was CEO of Asmacure Ltée, a venture-backed clinical stage biopharmaceutical company which he joined in late 2010. He recently led the sale of Asmacure Ltée to a Canada-based privately held life sciences firm.
Prior to Asmacure, Driscoll was the CEO and a director of Javelin Pharmaceuticals, a developer of acute care pain products, from March 2008 until July 2010 when he engineered the merger of Javelin with Hospira.
Driscoll has also held various senior management roles at Schering-Plough, ViroPharma and Reliant Pharmaceuticals. In 2007, he co-founded Pear Tree Pharmaceuticals, a privately-held developer of women's healthcare products.
Most recently, Eichler was an Executive Vice President and Principal of LCOR Incorporated, a national real estate development and investment company. Prior to that, he served in increasingly senior roles at The Linpro Company (the predecessor to LCOR), culminating in his position as Operating Partner, where he was responsible for new development and asset management activities across several metropolitan areas.
Prior to LCOR, Eichler was in the Real Estate Debt and Equity Finance Group at Merrill Lynch, Hubbard.
